Annual General Meeting

RNS Number : 8662K
Oxford Biomedica PLC
27 April 2010
 



 

 

 

FOR IMMEDIATE RELEASE

27 April 2010

 

OXFORD BIOMEDICA PLC

ANNUAL GENERAL MEETING

Oxford, UK - 27 April 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

 

Resolution 12 (to empower the Directors to issue of up to 10% of current issued shares without reference to the pre-emption rights specified in the Companies Act 2006) was withdrawn prior to the AGM. The Directors took account of the proxy votes cast prior to the meeting, and intend to consult further with shareholders and to reconsider this at the 2011 AGM. 

 

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

 

·     Resolution 10: to empower the Directors to allot equity securities, pursuant to section 551 of the Companies Act 2006 (the "Act"), up to an aggregate nominal amount of £1,810,197 with a further aggregate nominal amount of £1,810,197 authorised in connection with a rights issue, or where applicable, other proportionate offer;

 

·     Resolution 11: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares;

 

·     Resolution 13: to delete the provisions of the Company's former Memorandum and to adopt New Articles of Association, to implement changes brought in by Act; and

 

·     Resolution 14: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days notice.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting our website at www.oxfordbiomedica.co.uk

 

Certified copies of the document setting out the above resolutions passed at the 2010 AGM have been submitted to the UK Listing Authority and will shortly be made available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.

 

The results of the proxy voting in advance of the meeting shown below. On the Record Date (25 April 2010) there were 543,059,034 1p ordinary shares in issue, each carrying one vote per share.

 




 

 

 

Resolution

 

Votes 

For

Votes at 

Chairman's

Discretion

Votes at 

other proxy

Discretion

 

 Votes

Against

 

Votes 

Withheld

 

Total

votes cast

Result









Ordinary resolutions (1-10)






1

165,790,753

238,045

546,522

42,485

626,976

166,617,805

Passed









2

88,357,708

257,173

546,522

77,315,101

768,277

166,476,504

Passed









3

165,415,380

254,584

546,522

284,268

744,027

166,500,754

Passed









4

165,523,398

254,584

546,522

174,688

745,589

166,499,192

Passed









5

165,436,616

254,584

546,522

260,803

746,256

166,498,525

Passed









6

164,747,244

254,584

546,522

175,313

1,521,118

165,723,663

Passed









7

165,510,750

254,584

546,522

187,336

745,589

166,499,192

Passed









8

165,536,287

265,399

546,522

152,546

744,027

166,500,754

Passed









9

165,758,952

245,034

546,522

67,027

627,246

166,617,535

Passed









10

164,243,469

264,897

546,522

135,606

2,054,287

165,190,494

Passed







Special resolutions (11-14)






11

165,463,182

267,316

546,522

253,448

714,313

166,530,468

Passed









12

95,941,431

256,396

546,522

69,773,656

726,776

166,518,005

Withdrawn









13

165,617,351

279,841

546,522

126,209

674,858

166,569,923

Passed









14

163,396,762

263,382

546,522

2,395,193

642,922

166,601,859

Passed









 

 

 

-Ends-

 

 

For further information, please contact:

 


Oxford BioMedica plc:

John Dawson, Chief Executive Officer

 

Tel: +44 (0)1865 783 000

 

JPMorgan Cazenove Limited:

James Mitford/ Gina Gibson

 

Tel: +44 (0)20 7588 2828

 

City/Financial Enquiries:

Lisa Baderoon/ Mark Court

 Buchanan Communications

 

 

Tel: +44 (0)20 7466 5000

US Enquiries:

Thomas Fechtner

The Trout Group LLC

 

Tel: (646) 378 2900

 

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RAGKKODQDBKDQQB